# EU-1-09-597_public-assessment-report_20100129_20100129_olazax-epar-public-assessment-report.pdf

emes
European Medicines Agency
Evaluation of Medicines for Human Use
Doc.Ref .: EMEA/774081/2009
ASSESSMENT REPORT
FOR
OLAZAX
International Nonproprietary Name: olanzapine
Procedure No. EMEA/H/C/1087
Assessment Report as adopted by the CHMP with
all information of a commercially confidential nature deleted.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45
E-mail: mail@emea.europa.eu http://www.emea.europa.eu
C European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged.
TABLE OF CONTENTS
1.
BACKGROUND INFORMATION ON THE PROCEDURE
1.1
Submission of the dossier
2/15
1.2
Steps taken for the assessment of the product
4
2.
SCIENTIFIC DISCUSSION.
5
2.1
Introduction
5
2.2
Quality aspects
5
2.3
Non-Clinical aspects
7
2.4
Clinical Aspects
8
2.5
Pharmacovigilance
13
2.6
Overall conclusions, benefit/risk assessment and recommendation
14
Page
3
3
